Title: Paul Roben, Enterprise Ireland Biotechnology
1Paul Roben, Enterprise Ireland- Biotechnology
Commercialisation of Biotechnology Research
- Seizing Opportunities
BioIreland, November 14th 2006
2Innovation is Vital to Economic Progress
- Growing research capability is a core component
of the EUs drive to become the most competitive
and dynamic, knowledge-driven economy. - Ireland has embraced that challenge.
- Micheál Martin
- Minister for Enterprise, Trade and Employment
3Investment in RD
1.4 billion invested in RD - 645m SFI 605m
HEA.
4National Centres of Excellence
5Commercialisation of Research
Transfer of knowledge and technology from HEIs
into the marketplace is of crucial importance in
the establishment of a strong knowledge-based
economy Strategy for Science, Technology and
Innovation, 2006-2013
6(No Transcript)
7EI Commercialisation Funding
Over 80M investment in Applied Research
Commercialisation over the past 5 years
250 Principal Investigators linked into schemes
25 research institutes engaged in ARC services
8EI Bio Commercialisation Spending 2003-2006
Total 15.68m
9Anticipated 2007 Activity Levels
- 25 (8) Licences of Technology to Industry
- 12 (5) Spin Out companies from universities
- Recent Spin-out in Life Sciences
-
- Opsona Drug Development
- Biancamed Diagnostic and Monitoring
- Luxcel Drug Discovery Solutions
- Gas Sensor Solutions Oxygen Sensors
- Genable Gene-based therapeutics
- Celtic Catalysts Chiral Chemistry Solutions
-
10Industry- Academia Linkages
- Continuous technological change and innovation
are among the main determinants of productivity
growth in the industrial sector. - Increasingly, firms need more access to sources
of innovation. - The third level sector can be a key provider of
innovation.
11Strengthening the Technology Transfer Function
- Technology Transfer is the link between Research
and the Market - 30M Initiative to adequately resource TT
function - Central Support of that function.
- Increased awareness of the importance of TT
- Have clear efficient mechanisms of technology
transfer.
12Industry-Led Research
Industry-Led Research Programs
- 2-3M project-based, industry-led research
funding - Research conducted in academia under direction of
industry - Builds networks of partners in both sectors
- Encourages industry-focused research in HEIs.
- Industry can harness the innovative potential in
academia.
13Competence Centre Program (EI and IDA)
- 10M over 5 funding for industry-managed
research programmes. - Research centres focusing on strategically
important technologies where a clear industry
need is established - Under industrial management.
- Centres of international excellence designed to
maximise the commercial potential in Ireland of
IP generated. - Training programmes to address staffing needs of
industry in Ireland. - Flexibility model appropriate to individual
situations.
14Venture Capital Funding
A sustainable VC industry is vital for the
commercialisation of research - 175m
injection into VC market. - Potential to
leverage additional 1Bn investment
15Challenges in Biotechnology
- Weak, but developing commercial culture in
academic institutes. - Technology Transfer systems not yet optimal.
- Entrepreneurial culture underdeveloped.
- Small but growing indigenous industrial base- not
yet self-sustainable. - Business expenditure on RD lags behind
competitors.
16Conclusion
- Ireland started from a very low base.
- We are making progress and putting support
systems in at all levels. - There is a lot of work to do to ensure that the
potential of both the academic and industrial
sectors are realised and that both sectors
actively drive the development of the
knowledge-based economy in Ireland.
17Final Word..
- Our strategy is based on a shared vision of
placing Ireland firmly on the global map in terms
of the excellence of our research and its
application for the benefit of society. - Micheál Martin
18Thank You! Paul Roben Director, Biotechnology
Commercialisation Enterprise Ireland E-mail
paul.roben_at_enterprise-ireland.com